FOLH1 and bone neoplasm: Furthermore, while our analysis deliberately focused on PSMA-ligand PET/CT-driven bone tumor metrics to minimize the confounding influence of whole-body tumor burden, which may more accurately reflect RLT toxicity on the hematopoietic system, a limitation of this approach is that visceral and nodal metastases, which may also contribute to hematologic toxicity through inflammation processes, cytokine-driven marrow suppression, and indirect radiation effects, are not accounted for in our analysis.